

Novel Echocardiographic Parameter Assessing Pulmonary Vascular Resistance in Patients with Acyanotic Congenital Heart Disease

Muhammad Raihan Ramadhan Natadikarta,¹ Charlotte Johanna Cool,¹ Achmad Fitrah Khalid,¹ Norman Sukmadi,¹ Januar Wibawa Martha.¹

Abstract

Background: Pulmonary vascular resistance (PVR) is an important variable in the management of acyanotic congenital heart disease. Right heart catheterization (RHC) using an impedance catheter remains the gold standard for pulmonary vascular resistance (PVR) measurement. The ratio of peak tricuspid regurgitant velocity to the right ventricular outflow tract time-velocity integral (TRVmax/RVOTVTI) was presented as a reliable non-invasive method of estimating PVR. Recently, right ventricular 2-dimensional speckle tracking strain (RVGLS) was proven as a new promising parameter to evaluate PVR. This study was performed to examine whether this new non-invasive variable ratio (TRVmax/RVGLS) provides a clinically reliable method to determine pulmonary vascular resistance (PVR) obtained by echocardiography.

Methods: The cross-sectional observational study was performed on 56 patients with acyanotic congenital heart disease. All subjects underwent cardiac catheterization and echocardiography data was obtained within 24 hours. The ratio of TRVmax/RVOTVTI and TRVmax/RVGLS analysis was performed using receiver-operating characteristic curve analysis, and a cutoff value for the ratio was generated to determine PVR more than 5 WU.

Results: A TRVmax/RVOTVTI cutoff value of 0.21 provided a sensitivity of 77.1% and a specificity of 81% (CI 81% to 97.5%) and a TRVmax/RVGLS cutoff value of -23.16 provided a sensitivity of 74.3% and a specificity of 90.5% to determine PVR > 5 WU (CI 79.6% to 98.2%).

Conclusion: The echocardiography parameter (TRVmax/RVGLS) could serve as a dependable noninvasive method to predict PVR greater than 5 WU in acyanotic congenital heart disease patients.

(Indonesian J Cardiol. 2024;45:175-183)

Keywords: Congenital heart disease, Echocardiography, Pulmonary hypertension, Pulmonary vascular resistance, Right ventricle global longitudinal strain.

¹ Departement of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Bandung, Indonesia.

Correspondence:

Muhammad Raihan Ramadhan Natadikarta, Departement of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Bandung, Indonesia. Email: mraihanrn@gmail.com.

Introduction

Right heart catheterization (RHC) is the gold standard method for assessing the hemodynamics of individuals with pulmonary hypertension (PH), including determining pulmonary vascular resistance (PVR). Pulmonary vascular resistance is a hemodynamic variable that contributes to the management of patients with acyanotic congenital heart disease (CHD). It plays a critical role in guiding decisions regarding defect closure and evaluating clinical response to pharmacological therapy. However, RHC is considered an invasive procedure and not always available in several hospitals.¹⁻³

Doppler echocardiography has significantly impacted clinical medicine by its ability to estimate intracardiac hemodynamics non-invasively. The estimation of pulmonary artery systolic pressure (PASP) using trans tricuspid flow velocity (TTFV) is a fundamental aspect of echocardiographic assessment for suspected pulmonary hypertension (PH). However, pulmonary artery systolic pressure (PASP) does not provide a definition for pulmonary vascular resistance (PVR). Since flow and pressure variables can be estimated by echocardiography, we hypothesized that a measure of PVR might be accurately obtained by Doppler-derived variables. Echocardiographic estimation of PVR using the ratio of peak tricuspid regurgitant velocity (TRV) to the right ventricular outflow tract time-velocity integral (RVOT VTI) was presented as a reliable and widely-known non-invasive method to determine PVR (Abbas Formula).⁴⁻⁶ PVR is directly related to pressure difference (Δp) and inversely related to pulmonary flow (Q_p). TRV can be used as a surrogate of Δp , while RVOT VTI correlates with pulmonary flow (Q_p) which is influenced by RV function. However, doppler ultrasound beam alignment remains a crucial factor in acquiring adequate measurement of TRV and RVOT VTI. Right ventricular 2-dimensional speckle tracking strain is a promising parameter, as it is angle-independent, less load-dependent, and highly reproducible to assess RV function. Recent study shows that RV global longitudinal strain (RVGLS) correlates strongly with mean pulmonary arterial pressure (mPAP) and PVR in pulmonary arterial hypertension (PAH) patients.⁷⁻⁹ In acyanotic CHD, it is crucial to determine the timing of management, especially for closure

decisions. From previous studies and guidelines, PVR with a cut-off of 5 WU is commonly used for closure decisions.¹

Based on recent advancements in echocardiography measurement of RV function and its relation to haemodynamics, we hypothesized that a new echocardiography parameter can be proposed to predict PVR > 5 WU in acyanotic congenital heart disease patients.

Methods

This study is a cross-sectional observational study aimed at investigating echocardiography parameters and right heart catheterization results. The study protocol received approval from the Ethics Committee of Hasan Sadikin Hospital (DP.04.03/D.XIV.5.5/164/2024) and all the subjects gave informed consent. The investigation conforms with the principles outlined in the Declaration of Helsinki. We investigated all patients with CHD of different types, undergoing right heart catheterization (RHC). This study included patients visited our Grown Up Congenital Heart Disease Clinic who underwent RHC between August 2023 – August 2024. All subjects underwent echocardiographic examination with a maximum time interval of 24 hours before or after right heart catheterization. The inclusion criteria for this study were adults aged > 18 years with acyanotic CHD. Patients were excluded from the study if they had complex CHD, severe valvular heart disease, pregnancy, LVEF <50% by echocardiography, or poor echo window and right ventricular 2-dimensional speckle tracking strain cannot be performed. Potential sources of bias were managed by performing the echocardiography by different cardiologists and blinded for cardiac catheterization results.

Echocardiographic Examination

An echocardiographic examination was conducted using a Phillips Epic CVx. The device was equipped with an adult 1.5 – 4.3 MHz phased array transducer. The parasternal long and short axis views, as well as the apical four-chamber image, were employed as standard imaging techniques. Flow velocities were acquired via pulsed and continuous wave Doppler techniques. The measurement of pulmonary artery flow was conducted

Table 1. Baseline Demographics.

	Total (n=56)	PVR > 5 WU (n=35)	PVR < 5 WU (n=21)	P
Male/Female	13/43	6/26	7/14	0.165
Age (year)	31 (18–71)	30.00 (18 – 55)	39 (19 – 71)	0.009
Aetiology of CHD, n				
ASD	38	16	22	-
VSD	11	4	7	
PDA	6	0	6	
Other (ASD+VSD+PDA)	1	1	0	
NTproBNP	738 (35 – 25000)	961 (40-10729)	481 (35 – 25000)	0.178
Echocardiography				
LVEF (%)	62.45 ± 7.89	62.26 ± 8.42	62.76 ± 7.10	0.819
RVOTVTI (cm)	17.6 (7-68)	14 (7-33)	23 (12-68)	<0.001
TRVmax (m/s)	3.8 (1.3 – 5.4)	4.3 (1.74 – 5.4)	3.4 (1.3 – 4.8)	0.001
TRmeanPG (mmHg)	40.60 ± 19.09	44.79 ± 20.65	33.62 ± 13.97	0.033
PASP _{ECHO} (mmHg)	65.5 (9.76 – 127.36)	78.04 (15.11 – 127.36)	51.44 (9.76 – 95.16)	<0.001
mPAP _{ECHO} (mmHg)	56.50 (21 – 97)	48 (10.30 – 99)	38 (8.6 – 61)	0.028
RVGLS (%)	-17.25 ± 7.03	-14.26 ± 5.84	-22.23 ± 6.99	<0.001
RV basal diameter (mm)	50.50 ± 8.13	49.62 ± 7.17	51.95 ± 9.53	0.305
RV FAC (%)	34.5 (12.8 – 54)	24 (12.8 – 45)	40 (27.2 – 54.0)	<0.001
RVS' (m/s)	11.7 (4 – 18)	11 (4 – 18)	12 (10 – 17)	0.007
TAPSE (mm)	19.48 ± 5.05	17.41 ± 4.38	22.95 ± 4.17	<0.001
RA area (mm ²)	20.15 (10 – 50)	19.45 (10 – 41)	23 (10 – 50)	0.089
MPA (mm)	36.16 ± 7.50	47.63 ± 8.04	33.71 ± 5.90	0.058
TAPSE/PASP	0.27 (0.11 – 2.04)	0.20 (0.11 – 0.99)	0.47 (0.20 – 2.04)	<0.001
Right Heart Catheterization				
PASP _{CATH} (mmHg)	91.46 ± 31.35	110.14 ± 20.27	60.33 ± 19.42	<0.001
mPAP _{CATH} (mmHg)	56.48 ± 23.15	70.46 ± 16.52	33.19 ± 9.92	<0.001
PVR _{CATH} (WU)	8.74 (0.82 – 69.16)	16.18 (5.35 – 69.16)	2.37 (0.82 – 4.63)	<0.001
PARI _{CATH} (WU/m ²)	10.84 (0.22 – 64.40)	20.18 (8.75 – 64.40)	3.17 (0.22 – 7.75)	<0.001

PVR: Pulmonary Vascular Resistance; CHD: Congenital Heart Disease; ASD: Atrial Septal Defect; VSD: Ventricular Septal Defect; PDA: Patent Ductus Arteriosus; LVEF: Left Ventricle Ejection Fraction; RVOTVTI: Right Ventricular Outflow Tract Velocity Time Integral; TRVmax: Tricuspid regurgitant peak velocity; TRmeanPG: Tricuspid regurgitation mean pressure gradient; PASP: Pulmonary artery systolic pressure; mPAP: mean pulmonary artery pressure; RVGLS: Right ventricle global longitudinal strain; FAC: Fractional area change; TAPSE: Tricuspid annular plane systolic excursion; RA area: Right atrial

by positioning the pulsed wave Doppler sample volume precisely at the midpoint of the transpulmonary valve jet, which was acquired from the short-axis view. Continuous wave Doppler was used to measure the peak tricuspid pressure drop by obtaining retrograde systolic trans tricuspid flow from either the parasternal right ventricular input view or the apical four-chamber view. The Doppler recordings were conducted at a sweep speed of 50 - 100 mm/s, accompanied by an ECG (lead II) overlay. The study focused on assessing the strain of the right ventricular long-axis function using the

speckle-tracking echocardiography technique (STE). Pulmonary artery systolic pressure (PASP) calculated by $4 \times (\text{TRVmax})^2 + \text{estimated RA pressure}$. Variable RA pressure of 3/8/15 mmHg is determined based on IVC diameter and collapsibility. Mean pulmonary arterial pressure (mPAP) is calculated by the Aduen formula.¹⁰ All measurement was obtained as recommended by the American Society of Echocardiography.¹¹

Table 2. Echocardiographic parameters ratio between two groups.

Echocardiographic Parameters	PVR > 5 (n=35)	PVR < 5 (n=21)	p	AUC
TRVmax/RVOTVTI	0.24 (0.08 – 0.59)	0.12 (0.04-0.24)	0.001	0.893
TRVmax/RVGLS	-30.95 [-75 – (-10.81)]	-16.51 [-42 – (-5.67)]	0.001	0.889
TRmeanPG/RVGLS	-307.44 [-1043.48 - (55.53)]	-148.69 [-500 – (-20.67)]	0.001	0.822
PASPECHO/RVGLS	-574.59 [-1400 – (-93.85)]	-231.90 [-627.34 – (-48.53)]	0.001	0.884
mPAPECHO/RVGLS	-328.76 [-1076.09 – (74.16)]	-161.73 [-536.59 – (-30.67)]	0.001	0.833

RVOTVTI: Right Ventricular Outflow Tract Velocity Time Integral; TRVmax: Tricuspid regurgitant peak velocity; TRmeanPG: Tricuspid regurgitation mean pressure gradient; PASP: Pulmonary artery systolic pressure; mPAP: mean pulmonary artery pressure; RVGLS: Right ventricle global longitudinal strain.

Right Heart Catheterization

Cardiac interventionists who performed the invasive measurements were blinded to the echocardiographic findings. Venous access was achieved by putting an introducer sheath into the femoral vein. Subsequently, a catheterization was conducted using an MP-2 Catheter. The mean pulmonary arterial pressure (mPAP) was directly measured using a catheter placed in the pulmonary artery. Similarly, the mean left atrial pressure (mLAp) was recorded directly using a catheter implanted in the left atrium in a patient with an IAS defect (Atrial Septal Defect or Patent Foramen Ovale). Meanwhile, in patients without an IAS defect and no evidence of mitral stenosis, LVEDP measurement was performed with a pigtail catheter. The measurements were automatically derived from the pressure graphics. Blood samples were collected from the superior and inferior cava veins, right atrium, pulmonary artery, four pulmonary veins, and left atrium to determine oxygen saturation. Pulmonary flow (Qp) is measured by individual O₂ consumption divided by delta of pulmonary vein oxygen saturation (PVO₂) and pulmonary artery oxygen saturation (PAO₂). The pulmonary vascular resistance (PVR) was calculated using Indirect Fick’s method.^{2,3}

Statistical Analysis

In the demographic data section, continuous variables were presented as mean ± standard deviation (SD) for normally distributed data, median-interquartile range (IQR) for nonnormally distributed data, and categorical data presented as percentages or frequencies. Normality was evaluated using the 1-sample Kolmogorov–Smirnov test. The difference between invasive PVR as the gold

standard and echocardiography variables as independent variables was assessed by an independent t-test for normally distributed data and the Mann Whitney U test for nonnormally distributed data.

To assess the diagnostic value of the novel parameters, using PVR^{CATH} as the gold standard, receiver operating characteristic curves were plotted using a dichotomized function of PVR and a cut-off value of 5 wood units (WU). Confidence intervals of sensitivity and specificity were assessed. All analyses were performed on software (SPSS 25.0, SPSS Inc, Chicago, IL) and p<0.05 was considered statistically significant.

Results

There are 56 patients that remained in the final analysis. Baseline demography and standard echocardiographic parameters are presented in Table 1. The majority of patients were female, with most cases of ASD as aetiology of acyanotic congenital heart disease. There was no difference in LVEF, gender, RV basal diameter, RA Area, and MPA diameter between both groups. A total of 35 patients had PVR^{CATH} > 5 WU, while 21 patients had PVR^{CATH} < 5 WU. Median PVR^{CATH} was 8.74 (0.82 – 69.16) WU measured by RHC with significant differences between two groups.

TRVmax, RVOT VTI, TRmeanPG, PASP, mPAP (Aduen Formula), RVGLS, FAC, RVS’, TAPSE, and TAPSE/PASP show significant differences between groups. RVGLS was significantly more impaired in patients who had PVR > 5 WU. Based on a previous study, TRVmax/RVOTVTI shows an excellent correlation in predicting PVR. We perform analysis on several echocardiography parameters for predicting PVR




Figure 1. (a) receiver-operating characteristic curve for TRVmax/RVOTVTI with AUC 0.893 (CI 81% - 97.5%), (b) receiver-operating characteristic curve for TRVmax/RVGLS with AUC 0.889 (CI 79.6% - 98.2%).

> 5 WU. As the results, TRVmax/RVOTVTI, TRVmax/RVGLS, TRmeanPG/RVGLS, PASP/RVGLS, and mPAP/RVGLS show significant differences among both groups. (Table 2). Receiver operating characteristic (ROC) curves were calculated to evaluate the prediction of PVR > 5 WU by several echocardiographic parameters.

The area under the receiver-operating characteristic curve for TRVmax/RVOTVTI was calculated at 0.893. A TRVmax/RVOTVTI cutoff value of 0.13 provided a sensitivity of 91.4% and a specificity of 52.4% to determine PVR > 5 WU, meanwhile, a cutoff value of 0.21 provided a sensitivity of 77.1% and a specificity of 81% (CI 81% to 97.5%). The area under the receiver-operating characteristics curve for TRVmax/RVGLS was calculated at 0.889. This result was comparable with the previous formula in predicting PVR (TRVmax/RVOTVTI). A TRVmax/RVGLS cutoff value of -19.61 provided a sensitivity of 91.4% and a specificity of 76.2% to determine PVR > 5 WU, meanwhile, a cutoff value of -23.16 provided a sensitivity of 74.3% and a specificity of 90.5% to determine PVR > 5 WU (CI 79.6% to 98.2%).

Discussion

Previous studies have attempted to obtain a non-invasive measurement of PVR. The ratio of TRVmax to RVOT VTI was the most studied to predict PVR.^{4-6,12-22} However, certain limitations was found to predict PVR in certain conditions such as unreliable formula in high PVR subjects. Recent advancement of RV function assessment shows RV GLS measurement can be performed to measure RV function and several studies shows excellent relationship to mPAP and PVR.^{7-9,23,24} We present the process of developing novel echocardiography parameter to predict PVR. Our study shows, TRVmax/RVGLS have excellent performance in predicting PVR > 5 WU in patient with acyanotic congenital heart disease with cut-off point of -19.61 provided sensitivity 91.4% and specificity 76.2%.

Volume and/or pressure overload lead to alteration in RV physiology and function. Increase of RV pressure and wall stress results in RV dysfunction including RV dilatation, reduced RV wall motion, intraventricular, and interventricular RV dyssynchrony. Conventional RV functional parameters such as TAPSE, RV S' and RVFAC in early stages of PH can remain normal, consequently RV strain analysis is favourable for detecting subtle hemodynamic changes. Standard

echocardiographic parameters (TAPSE, S', RVFAC, etc) are used for evaluation of RV function but they are affected by some factors such as image quality, angle dependent, heart motion or ventricular loading condition. RV strain has several advantages such as angle independency, less load dependency, accuracy in measurement of regional myocardial deformation, high availability, low cost, and high reproducibility.^{9,11,25,26}

Right ventricular function has an important prognostic role in various condition, especially patient with pulmonary arterial hypertension (PAH). Changes in RVGLS value in congenital heart disease is not well defined in patient whom had chronic volume or pressure overload, but RVGLS has been shown to be a robust marker of RV function in patients with PAH and was proved to be strong predictor of mortality. However, there are several limitation or issues regarding the use of RVGLS such as no agreement about cut off normal values, demand high temporal resolution, visualization of RV endocardial border, and sometimes problem with window in term of poor visualization of RV free wall.^{9,11,23-27}

Pulmonary hypertension in adult acyanotic congenital heart disease should be evaluated particularly and determination of PVR is mandatory. PVR was associated with outcome of closure intervention in congenital heart disease and patients with PVR > 5 are likely to have worse clinical outcome.²⁸⁻³² Previous study by Abbas et. al. shows TRVmax/RVOTVTI has excellent performance in predicting PVR value.^{4,6} In this study, TRVmax/RVOTVTI shows similar results with cutoff value of 0.13 provided a sensitivity of 91.4% and a specificity of 52.4% in predicting PVR > 5 WU. Abbas et. al. provided 0.175 as cutoff value for TRVmax/RVOTVTI with good sensitivity of 77% and specificity of 81% in predicting PVR > 2 WU.⁴ Our result show similar area under the curve but with slightly differences in sensitivity and specificity cutoff value in predicting PVR (> 5 WU vs > 2 WU).

Prior researchers have documented the utilization of different doppler parameters for the assessment of pulmonary vascular resistance. The primary focus of these work has been on determining the timing of events such as the duration of right ventricular pre-ejection and ejection, the acceleration time of the right ventricular outflow tract velocity, and the velocities of flow propagation. Other studies show decent correlation

between echocardiographic parameter estimation of PVR with PVR by RHC, but none of them using global longitudinal strain in their parameters.^{4,6,19-22,33} Our study shows significant correlation between TRVmax/RVGLS and PVR^{CATH} and cut-off point of -19.61 provided sensitivity 91.4% and specificity 76.2% in terms of predicting PVR > 5 WU.

Our study has showed that our novel parameter TRVmax/RVGLS may have better performance in determining PVR in adult acyanotic congenital heart disease with pulmonary hypertension. We hope our models can be applied in centre that with no catheterization laboratory, in addition to start, evaluating medical therapy, and determine definite management in adult patients with acyanotic congenital heart disease and pulmonary hypertension. If the patient had estimated PVR > 5 WU, we can start medical therapy and refers to cardiac catheterization centre for invasive evaluation. Conversely, if the patient had estimated PVR < 5 WU, prompt referral to cardiac catheterization centre for closure management is a priority.

Limitation

Limitations inherent to the doppler technique are related to proper alignment of the ultrasound beam and have been reported elsewhere. Inability to obtain the tricuspid regurgitation jet is also a concern and has been addressed in the respective publications. Also, the peak TRV may vary with respiration, so using an average of multiple beats, rather than the maximum velocity obtained during sinus rhythm, may be a more appropriate representation of this parameter. RV GLS measurement have several weaknesses such as demand high temporal resolution, visualization of RV endocardial border, and sometimes have problem with window in term of poor visualization of RV free wall, leading to improper measurement of RV GLS.

All patient in this study had mPAP >20 mmHg thus this new method represents PH population in acyanotic congenital heart disease should be interpret cautiousl.

Conclusion

The novel echocardiography parameters TRVmax/RVGLS, which are based on a non-invasive formula for

predicting PVR, have a significant correlation with the gold standard measure and demonstrate high accuracy with excellent sensitivity and specificity in detecting individuals with elevated pulmonary vascular resistance (PVR > 5 WU) for patient with acyanotic congenital heart disease. A cut-off point of -19.61 was proposed as a predictor of PVR > 5 WU.

Ethics approval and consent to participate

The research was performed in accordance with the Declaration of Helsinki and was approved by the Hasan Sadikin Hospital Ethics Committee.

Informed consent

Written informed consent was obtained from each participant.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Competing interest

I have nothing to declare.

Funding

This research was not funded.

Declaration of generative AI and AI-assisted technologies in the writing process

Not applicable.

Acknowledgements

Not applicable.

Author Contributions

All authors write and review the manuscript. MRRN and CJC took part on conceptualization. MRRN, CJC, and AFK took part on data curation. CJC and AFK took part on investigation. MRRN, JWM, and CJC took part on project administration. MRRN, CJC, and NS took part on data analysis. JWM, CJC, and AFK took part on supervision. MRRN, CJC, JWM, AFK, and NS took part on methodology.

List of Abbreviations

CHD	Congenital Heart Disease
mPAP	Mean pulmonary arterial pressure
mLAP	Mean left atrial pressure
PAO2	Pulmonary Artery Oxygen Saturation
PASP	Pulmonary artery systolic pressure
PVR	Pulmonary vascular resistance
PH	Pulmonary hypertension
PVO2	Pulmonary vein oxygen saturation
RHC	Right heart catheterization
RVGLS	Right ventricle global longitudinal strain
TTFV	Trans tricuspid flow velocity
TRVmax	Tricuspid regurgitant peak velocity
TRmeanPG	Tricuspid regurgitation mean pressure gradient
RVOTVTI	Right Ventricular Outflow Tract Velocity Time Integral

References

1. Baumgartner H, de Backer J, Babu-Narayan S V., Budts W, Chessa M, Diller GP, et al. 2020 ESC Guidelines for the management of adult congenital heart disease. *European Heart Journal*. Oxford University Press; 2021. p. 563–645.
2. Tamimi O, Mohammed MHA. Pulmonary Vascular Resistance Measurement Remains Keystone in Congenital Heart Disease Management. *Front Cardiovasc Med* [Internet]. *Frontiers Media SA*; 2021 Mar 31;8.

3. Callan P, Clark AL. Right heart catheterisation: indications and interpretation. *Heart* [Internet]. BMJ Publishing Group Ltd and British Cardiovascular Society; 2016 Jan 15;102(2):147–57.
4. Abbas AE, Fortuin FD, Schiller NB, Appleton CP, Moreno CA, Lester SJ. A simple method for noninvasive estimation of pulmonary vascular resistance. *J Am Coll Cardiol*. Elsevier; 2003 Mar 19;41(6):1021–7.
5. Roule V, Labombarda F, Pellissier A, Sabatier R, Lognoné T, Gomes S, et al. Echocardiographic assessment of pulmonary vascular resistance in pulmonary arterial hypertension. *Cardiovasc Ultrasound* [Internet]. BioMed Central; 2010 Jun 7;8(1):1–6.
6. Abbas AE, Franey LM, Marwick T, Maeder MT, Kaye DM, Vlahos AP, et al. Noninvasive assessment of pulmonary vascular resistance by doppler echocardiography. *Journal of the American Society of Echocardiography* [Internet]. Elsevier; 2013 Oct 1;26(10):1170–7.
7. Park JH, Negishi K, Kwon DH, Popovic ZB, Grimm RA, Marwick TH. Validation of Global Longitudinal Strain and Strain Rate as Reliable Markers of Right Ventricular Dysfunction: Comparison with Cardiac Magnetic Resonance and Outcome. *J Cardiovasc Ultrasound* [Internet]. BMC; 2014 Sep 1;22(3):113.
8. Csadi DR, Morvai Illes DB, Jdid Mahmoud DS, Monoki DM, Varga PA, Agoston DG. The relationship between RV strain and haemodynamic parameters in patients with pulmonary arterial hypertension. *Eur Heart J Cardiovasc Imaging* [Internet]. Oxford Academic; 2023 Jun 19;24(Supplement_1):649.
9. Seo HS, Lee H. Assessment of Right Ventricular Function in Pulmonary Hypertension with Multimodality Imaging. *J Cardiovasc Imaging* [Internet]. BMC; 2018 Dec 1;26(4):189.
10. Aduen JF, Castello R, Lozano MM, Hepler GN, Keller CA, Alvarez F, et al. An Alternative Echocardiographic Method to Estimate Mean Pulmonary Artery Pressure: Diagnostic and Clinical Implications. *Journal of the American Society of Echocardiography* [Internet]. Elsevier; 2009 Jul 1;22(7):814–9.
11. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. *J Am Soc Echocardiogr* [Internet]. J Am Soc Echocardiogr; 2010 Jul;23(7):685–713.
12. Dahiya A, Vollbon W, Jellis C, Prior D, Wahi S, Marwick T. Echocardiographic assessment of raised pulmonary vascular resistance: application to diagnosis and follow-up of pulmonary hypertension. *Heart* [Internet]. Heart; 2010 Dec;96(24):2005–9.
13. Rajagopalan N, Simon MA, Suffoletto MS, Shah H, Edelman K, Mathier MA, et al. Noninvasive estimation of pulmonary vascular resistance in pulmonary hypertension. *Echocardiography* [Internet]. Echocardiography; 2009 May;26(5):489–94.
14. Roule V, Labombarda F, Pellissier A, Sabatier R, Lognoné T, Gomes S, et al. Echocardiographic assessment of pulmonary vascular resistance in pulmonary arterial hypertension. *Cardiovasc Ultrasound* [Internet]. Cardiovasc Ultrasound; 2010;8(1).
15. Farzaneh-Far R, McKeown BH, Dang D, Roberts J, Schiller NB, Foster E. Accuracy of Doppler-Estimated Pulmonary Vascular Resistance in Patients Before Liver Transplantation. *American Journal of Cardiology* [Internet]. Elsevier; 2008 Jan 15;101(2):259–62.
16. Ajami GH, Cheriki S, Amoozgar H, Borzouee M, Soltani M. Accuracy of Doppler-derived estimation of pulmonary vascular resistance in congenital heart disease: an index of operability. *Pediatr Cardiol* [Internet]. Pediatr Cardiol; 2011 Dec;32(8):1168–74.
17. Albers J, Ister D, Kayhan N, Vahl CF. Postoperative non-invasive assessment of pulmonary vascular resistance using Doppler echocardiography. *Interact Cardiovasc Thorac Surg* [Internet]. Interact Cardiovasc Thorac Surg; 2011 Dec;13(6):579–84.
18. Kouzu H, Nakatani S, Kyotani S, Kanzaki H, Nakanishi N, Kitakaze M. Noninvasive Estimation

- of Pulmonary Vascular Resistance by Doppler Echocardiography in Patients With Pulmonary Arterial Hypertension. *American Journal of Cardiology* [Internet]. Elsevier; 2009 Mar 15;103(6):872–6.
19. Opotowsky AR, Clair M, Afilalo J, Landzberg MJ, Waxman AB, Moko L, et al. A Simple Echocardiographic Method To Estimate Pulmonary Vascular Resistance. *Am J Cardiol* [Internet]. NIH Public Access; 2013 Sep 9;112(6):873.
 20. Haddad F, Zamanian R, Beraud AS, Schnittger I, Feinstein J, Peterson T, et al. A Novel Non-Invasive Method of Estimating Pulmonary Vascular Resistance in Patients With Pulmonary Arterial Hypertension. *Journal of the American Society of Echocardiography*. Mosby Inc.; 2009;22(5):523–9.
 21. Selimovic N, Rundqvist B, Bergh CH, Andersson B, Petersson S, Johansson L, et al. Assessment of Pulmonary Vascular Resistance by Doppler Echocardiography in Patients With Pulmonary Arterial Hypertension. *Journal of Heart and Lung Transplantation*. 2007 Sep;26(9):927–34.
 22. Lindqvist P, Söderberg S, Gonzalez MC, Tossavainen E, Henein MY. Echocardiography based estimation of pulmonary vascular resistance in patients with pulmonary hypertension: a simultaneous Doppler echocardiography and cardiac catheterization study. *European Journal of Echocardiography* [Internet]. Oxford Academic; 2011 Dec 1;12(12):961–6.
 23. Li Y, Xie M, Wang X, Lu Q, Fu M. Right ventricular regional and global systolic function is diminished in patients with pulmonary arterial hypertension: A 2-dimensional ultrasound speckle tracking echocardiography study. *International Journal of Cardiovascular Imaging* [Internet]. Springer; 2013 Mar 6;29(3):545–51.
 24. Pirat B, McCulloch ML, Zoghbi WA. Evaluation of Global and Regional Right Ventricular Systolic Function in Patients With Pulmonary Hypertension Using a Novel Speckle Tracking Method. *American Journal of Cardiology* [Internet]. Elsevier; 2006 Sep 1;98(5):699–704.
 25. Konstam MA, Kiernan MS, Bernstein D, Bozkurt B, Jacob M, Kapur NK, et al. Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association. *Circulation* [Internet]. Circulation; 2018 May 15;137(20):e578–622.
 26. Muraru D, Haugaa K, Donal E, Stankovic I, Voigt JU, Petersen SE, et al. Right ventricular longitudinal strain in the clinical routine: a state-of-the-art review. *Eur Heart J Cardiovasc Imaging* [Internet]. Oxford Academic; 2022 Jun 21;23(7):898–912.
 27. Ünlü S, Bézy S, Cvijic M, Duchenne J, Delcroix M, Voigt JU. Right ventricular strain related to pulmonary artery pressure predicts clinical outcome in patients with pulmonary arterial hypertension. *Eur Heart J Cardiovasc Imaging* [Internet]. Oxford Academic; 2023 Apr 24;24(5):635–42.
 28. Humenberger M, Rosenhek R, Gabriel H, Rader F, Heger M, Klaar U, et al. Benefit of atrial septal defect closure in adults: impact of age. *Eur Heart J* [Internet]. 2010 Mar;32(5):553.
 29. Yong G, Khairy P, De Guise P, Dore A, Marcotte F, Mercier LA, et al. Pulmonary arterial hypertension in patients with transcatheter closure of secundum atrial septal defects: a longitudinal study. *Circ Cardiovasc Interv* [Internet]. Circ Cardiovasc Interv; 2009 Oct;2(5):455–62.
 30. Manes A, Palazzini M, Leci E, Bacchi Reggiani ML, Branzi A, Galiè N. Current era survival of patients with pulmonary arterial hypertension associated with congenital heart disease: a comparison between clinical subgroups. *Eur Heart J* [Internet]. Eur Heart J; 2014;35(11):716–24.
 31. D’Alto M, Romeo E, Argiento P, Correr A, Santoro G, Gaio G, et al. Hemodynamics of patients developing pulmonary arterial hypertension after shunt closure. *Int J Cardiol* [Internet]. Int J Cardiol; 2013 Oct 9;168(4):3797–801.
 32. Steele PM, Fuster V, Cohen M, Ritter DG, McGoon DC. Isolated atrial septal defect with pulmonary vascular obstructive disease—long-term follow-up and prediction of outcome after surgical correction. *Circulation* [Internet]. Circulation; 1987;76(5):1037–42.
 33. Cool CJ, Khalid AF, Sukmadi N, Akbar MR, Setiabudiawan B, Rahayuningsih SE. The association of right ventricular-pulmonary arterial coupling and pulmonary vascular resistance in adult patients with uncorrected atrial septal defect. *BMC Cardiovasc Disord* [Internet]. BMC Cardiovasc Disord; 2024 Dec 1;24(1).